Source Count: 14 | Weighted Score: 36 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 2, 2026
Keywords: ketamine, esketamine, spravato, depression, treatment-resistant, nmda-receptor, dissociative, glutamate, rapid-antidepressant, suicidal-ideation
Category Tags: ketamine-therapy, psychopharmacology, depression-treatment, dissociative-medicine
Cross-References: Y_1_16 — MDMA Therapy · Y_3_17 — Mindfulness Neuroscience · X_3_23 — Regenerative Medicine

QUICK SUMMARY

Ketamine — a dissociative anesthetic synthesized by Calvin Stevens at Parke-Davis in 1962 and first used clinically by Edward Domino and Guenter Corssen in 1966 — has emerged as a revolutionary treatment for treatment-resistant depression (TRD), producing rapid antidepressant effects within hours, in contrast to conventional antidepressants (SSRIs, SNRIs) that require 4–6 weeks. KEY FINDING The landmark study by Berman et al. (2000, Biological Psychiatry) demonstrated that a single subanesthetic intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) produced significant antidepressant effects within 4 hours in patients with major depressive disorder — a finding replicated and extended by Zarate et al. (2006, Archives of General Psychiatry, n=18, crossover design: 71% response rate at 24 hours vs. 0% for placebo, with effects lasting ~1 week). Ketamine acts primarily as an NMDA (N-methyl-D-aspartate) receptor antagonist, blocking glutamate signaling at these receptors, which triggers a cascade of downstream effects: increased AMPA receptor activation, release of BDNF (brain-derived neurotrophic factor), activation of the mTOR (mechanistic target of rapamycin) signaling pathway, and rapid synaptogenesis — the growth of new dendritic spines in the prefrontal cortex within hours (Li et al., 2010, Science). This rapid synaptoplastic mechanism contrasts fundamentally with the slow monoamine-based mechanism of SSRIs. In March 2019, the FDA approved esketamine (Spravato, the S-enantiomer of ketamine, delivered as a nasal spray) for TRD in conjunction with an oral antidepressant — the first mechanistically novel antidepressant approved in decades. Daly et al. (2019, JAMA Psychiatry: Phase 3 TRANSFORM-2 trial, n=223) showed esketamine + antidepressant was superior to placebo + antidepressant at Day 28 (−4.0 point difference on MADRS, p=0.020). Ketamine has also shown rapid efficacy against acute suicidal ideation (Wilkinson et al., 2018, American Journal of Psychiatry: meta-analysis of 10 RCTs showing rapid anti-suicidal effects within 24 hours). Key concerns include: dissociative side effects during infusion, abuse potential (Schedule III), transient blood pressure elevation, and the need for repeated dosing (effects typically last 3–14 days). The proliferation of ketamine infusion clinics (>750 in the US by 2023) has raised regulatory and quality-of-care debates.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

• KEY FINDING Rapid antidepressant effects: Zarate et al. (2006) demonstrated 71% response rate at 24 hours with a single IV ketamine infusion (0.5 mg/kg) in TRD patients. Effects peaked at 24–72 hours and typically dissipated within 7–14 days. This finding has been replicated in >20 randomized controlled trials.
• NMDA receptor mechanism: ketamine blocks NMDA receptors on GABAergic interneurons, disinhibiting glutamate release, which activates AMPA receptors on pyramidal neurons, triggering BDNF release and mTOR-dependent synaptogenesis. Li et al. (2010, Science) demonstrated rapid dendritic spine formation in rat prefrontal cortex within 2 hours of ketamine administration, with reversal of chronic stress-induced synaptic deficits.
• FDA approval of esketamine: Spravato (esketamine nasal spray) approved March 2019 for TRD in adults (taken with oral antidepressant, administered in certified healthcare settings with 2-hour post-dose observation due to dissociative effects and sedation). Extended indication for major depressive disorder with acute suicidal ideation approved August 2020.
• Anti-suicidal effects: Wilkinson et al. (2018, American Journal of Psychiatry) meta-analysis of 10 double-blind RCTs (n=167) found ketamine rapidly reduced suicidal ideation within 24 hours (OR 0.27 for suicidal ideation at Day 1). Canuso et al. (2018, AJP: ASPIRE-1 trial) confirmed esketamine's rapid anti-suicidal effect in the emergency department setting.
• Dissociative and adverse effects: common side effects include dissociation (feeling of unreality, perceptual disturbances), dizziness, nausea, elevated blood pressure (typically transient, resolving within 2 hours), and sedation. These occur primarily during and shortly after dosing (~60–90 minutes post-administration).

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

• Arketamine (R-ketamine): the R-enantiomer of ketamine may have greater and longer-lasting antidepressant effects with fewer dissociative side effects than S-ketamine (esketamine), based on preclinical rodent studies (Zhang et al., 2014, Pharmacology, Biochemistry and Behavior). Phase 2 clinical trials of arketamine (PCN-101) by Perception Neuroscience are ongoing. If confirmed, this would represent a significant advance.
• Repeated dosing and maintenance: most clinical protocols involve 6 infusions over 2–3 weeks (induction phase), followed by maintenance infusions at varying intervals. Optimal maintenance schedules are not well established. Phillips et al. (2019, American Journal of Psychiatry) found that weekly or biweekly ketamine infusions maintained response in ~70% of initial responders over 4 weeks.
• Opioid system involvement: Williams et al. (2018, AJP) found that pretreatment with naltrexone (an opioid antagonist) blocked ketamine's antidepressant effects (n=12 crossover, 7/7 responded to ketamine alone, 1/7 responded with naltrexone pretreatment) — suggesting that the opioid receptor system may partially mediate ketamine's antidepressant action. This finding is controversial and challenges the pure NMDA/glutamate hypothesis.
• Neuroplasticity and default mode network: ketamine may reduce depression by disrupting default mode network (DMN) hyperconnectivity — a hallmark of rumination in depression. Evans et al. (2018) found that ketamine acutely reduced DMN functional connectivity, correlating with symptom improvement.
• Ketamine infusion clinics: the rapid proliferation of commercial ketamine clinics operates in a regulatory gray area — most use racemic ketamine (off-label use: legal but not FDA-approved for depression), and practice quality varies widely. Professional organizations (American Psychiatric Association, 2017 consensus statement) have called for standardized protocols and oversight.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

• Whether ketamine or its metabolites (e.g., hydroxynorketamine) could be developed into oral formulations retaining rapid antidepressant effects without dissociative side effects is under investigation but unproven.
• Whether ketamine-assisted psychotherapy (combining the pharmacological effects with therapeutic processing during the dissociative experience) adds benefit beyond ketamine alone is supported by some open-label studies but not yet confirmed in rigorous RCTs.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

• Claims that ketamine is a "cure" for depression. It produces rapid but temporary relief; most patients relapse without maintenance treatment. DEBUNKED as a standalone curative intervention.
• Claims that recreational ketamine use provides the same therapeutic benefit as controlled clinical infusions. Dose, setting, monitoring, and psychological context differ fundamentally.

Counter-Arguments & Criticisms

On long-term safety: Chronic ketamine use is associated with urological damage (ketamine cystitis), cognitive impairment, and dependence. Long-term safety data for clinical antidepressant use (years of maintenance dosing) are limited.

On mechanism: The field remains divided on whether NMDA antagonism, AMPA activation, opioid involvement, or synaptic plasticity is the primary mediator — likely all contribute.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Berman, Robert, Angela Cappiello, Amit Anand, Dan Oren, George Heninger, Dennis Charney; John Krystal. | 2000 | "Antidepressant Effects of Ketamine in Depressed Patients" | Biological Psychiatry | ∅ | 47.4::351–354 | ∅ | ∅ | doi:10.1016/S0006-3223(99)00230-9 | ∅ | ∅ | ∅
2. Zarate, Carlos, Jaskaran Singh, Paul Carlson, Nancy Brutsche, Rezvan Ameli, David Luckenbaugh, Dennis Charney; Husseini Manji | 2006 | "A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression" | Archives of General Psychiatry | ∅ | 63.8::856–864 | ∅ | ∅ | doi:10.1001/archpsyc.63.8.856 | ∅ | ∅ | ∅
3. Li, Nanxin, Bong Lee, Rong-Jian Liu, Mounira Banasr, Jason Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian; Ronald Duman | 2010 | "mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists" | Science | ∅ | 329.5994::959–964 | ∅ | ∅ | doi:10.1126/science.1190287 | ∅ | ∅ | ∅
4. Daly, Ella, Jaskaran Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Rosanne Shelton, Michael Thase, Andrew Winokur, Ludo Van Nueten, Husseini Manji; Wayne Drevets | 2019 | "Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial" | JAMA Psychiatry | ∅ | 75.2::139–148 | ∅ | ∅ | doi:10.1001/jamapsychiatry.2017.3739 | ∅ | ∅ | ∅
5. Wilkinson, Samuel, Elizabeth Ballard, Michael Bloch, Sanjay Mathew, James Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos Zarate; Gerard Sanacora | 2018 | "The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis" | American Journal of Psychiatry | ∅ | 175.2::150–158 | ∅ | ∅ | doi:10.1176/appi.ajp.2017.17040472 | ∅ | ∅ | ∅
6. Williams, Nolan, Boris Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David Lyons, Carolyn Rodriguez; Alan Schatzberg | 2018 | "Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism" | American Journal of Psychiatry | ∅ | 175.12::1205–1215 | ∅ | ∅ | doi:10.1176/appi.ajp.2018.18020138 | ∅ | ∅ | ∅
7. Krystal, John, Chadi Abdallah, Gerard Sanacora, Dennis Charney; Ronald Duman | 2019 | "Ketamine: A Paradigm Shift for Depression Research and Treatment" | Neuron | ∅ | 101.5::774–778 | ∅ | ∅ | doi:10.1016/j.neuron.2019.02.005 | ∅ | ∅ | ∅
8. Domino, Edward | 2010 | "Taming the Ketamine Tiger" | Anesthesiology | ∅ | 113.3::678–684 | ∅ | ∅ | doi:10.1097/ALN.0b013e3181ed09a2 | ∅ | ∅ | ∅
9. Phillips, Jennifer, Sanjay Norris, Jeanne Talbot, Mark Birmingham, Tiffany Hatchard, Alicia Ortiz, Olabisi Owoeye, Lisa Batten; Pierre Bhatt | 2019 | "Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial" | American Journal of Psychiatry | ∅ | 176.5::401–409 | ∅ | ∅ | doi:10.1176/appi.ajp.2018.18070834 | ∅ | ∅ | ∅
10. Hashimoto, Kenji | 2019 | "Rapid-Acting Antidepressant Ketamine, Its Metabolites and Other Candidates: A Historical Overview and Future Perspective" | Psychiatry and Clinical Neurosciences | ∅ | 73.10::613–627 | ∅ | ∅ | doi:10.1111/pcn.12902 | ∅ | ∅ | ∅
11. Canuso, Carla, Jaskaran Singh, Maggie Fedgchin, Larry Alphs, Rosanne Lane, Pilar Lim, Christine Pinter, Deborah Hough, Ella Daly, Regina Binneman; Wayne Drevets | 2018 | "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide" | American Journal of Psychiatry | ∅ | 175.7::620–630 | ∅ | ∅ | doi:10.1176/appi.ajp.2018.17060720 | ∅ | ∅ | ∅
12. Abdallah, Chadi, Lynnette Averill, Ralitza Gueorguieva, Selin Goktas, Prerana Purohit, Mohini Ranganathan, Mohamed Sherif, Deepak D'Souza, Daniel Forber, Richard Southwick; John Krystal | 2020 | "Modulation of the Antidepressant Effects of Ketamine by the mTORC1 Inhibitor Rapamycin" | Neuropsychopharmacology | ∅ | 45.6::990–997 | ∅ | ∅ | doi:10.1038/s41386-020-0644-9 | ∅ | ∅ | ∅
13. Sanacora, Gerard, Mark Frye, Wade McDonald, Sanjay Mathew, Maurizio Fava, Paul Gassaway, Amit Jober; Carlos Zarate | 2017 | "A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders" | JAMA Psychiatry | ∅ | 74.4::399–405 | ∅ | ∅ | doi:10.1001/jamapsychiatry.2017.0080 | ∅ | ∅ | ∅
14. Zanos, Panos, Ruin Moaddel, Patrick Morris, Polymnia Georgiou, Jonathan Fischell, Greg Elmer, Marisela Alkondon, Peng Yuan, Harvey Pribut, Nagendra Singh, Katrina Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl Mayo, Irving Wainer, Edson Albuquerque, Scott Thompson, Craig Thomas, Carlos Zarate; Todd Gould | 2016 | "NMDAR Inhibition-Independent Antidepressant Actions of Ketamine Metabolites" | Nature | ∅ | 533.7604::481–486 | ∅ | ∅ | doi:10.1038/nature17998 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 2, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S0006-3223(99)00230-9. Corpus hygiene campaign, Phase 4, 2026-07-29.